Semaglutide guide
What is the difference between FDA-approved, compounded, and salt-form Semaglutide?
A source-led explanation of regulatory status, product quality questions, and why similar names do not establish equivalence.
In brief
FDA-approved semaglutide products are reviewed as specific finished medicines. Compounded drugs are not FDA-approved, and FDA has warned that semaglutide salt forms such as semaglutide sodium or acetate are different active ingredients from the base form used in approved products. A name match is not proof of equivalence, quality, or lawful availability.
Why this question comes up
A concern worth understanding clearly
Names that sound alike can suggest that products are interchangeable when their regulatory status, active ingredient form, manufacturing controls, and labeling differ. A name match alone cannot establish quality, equivalence, or lawful availability.
Research context
What research can tell us
Regulatory review attaches to a particular drug product, formulation, manufacturing controls, labeling, and indication. The active-ingredient name alone does not verify identity, concentration, sterility, safety, effectiveness, or legal compounding status.
What has been studied
What this cannot answer
FDA distinguishes approved products from unapproved compounded and salt-form products
FDA communications explain that compounded products are not FDA-approved and address concerns about semaglutide salt forms, quality, and dosing errors in compounded injectable products.
How to interpret it: This is a regulatory and product-quality distinction, not a purchasing guide or a claim that one can identify a product's quality from marketing alone.
Study limits
- Regulatory status can change and should be checked at the source
- A webpage cannot verify an individual product, prescription, pharmacy, or supply claim
What this cannot answer
- FDA communications describe broad regulatory and safety concerns, not quality testing of every marketed item.
- The absence of a visible problem does not establish sterility, concentration, or equivalence.
Safety and uncertainty
When this needs medical help
What is known
- FDA states that compounded drugs are not FDA-approved and has described quality and dosing-error concerns for some unapproved GLP-1 products.
Seek urgent care when
- A suspected overdose, severe reaction, or serious symptom should be handled through urgent medical care or poison-control resources as appropriate, not an online product comparison.
What remains unknown
- This page cannot authenticate a vial, a website claim, a pharmacy, or a seller's document.
When to contact a clinician
For questions about a prescribed product, a dispensing concern, or whether a medicine is appropriate, speak with a licensed prescriber or pharmacist. This site does not source products, validate sellers, or advise on use of unapproved medicines.
Need help understanding this information?Continue exploring
Questions you may still have
These guides add useful context without replacing personal medical advice.
Common follow-ups
More questions, answered carefully
Are compounded products FDA-approved?
No. FDA states that compounded drugs are not FDA-approved.
Are semaglutide sodium or acetate simply alternate names for approved semaglutide?
FDA says these are different active ingredients from the semaglutide base used in approved products.
Sources
Sources you can check
Last reviewed 2026-08-06. These links show the studies, prescribing information, and regulator material used for this page.
- 1. FDA's concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration - Accessed 2026-08-06 - Supports: compounded-product context, salt-form distinction, quality uncertainty
- 2. FDA alert on dosing errors with compounded injectable semaglutide products
U.S. Food and Drug Administration - Accessed 2026-08-06 - Supports: concentration variation, measurement-error risk, adverse-event context
- 3. WEGOVY (semaglutide) prescribing information
U.S. Food and Drug Administration - Accessed 2026-08-06 - Supports: approved-use context, mechanism, warnings, adverse reactions